Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat vs BPA in Non-operable CTEPH
NCT02634203Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2016
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Pulmonary Vascular Resistance at 26 weeks. Started Jan 2016; status: completed.
Beyond the preview
Go deeper on NCT02634203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634203.